Drug Applications Face Rejection As China FDA Starts 'Intensive Review'
This article was originally published in SRA
Executive Summary
In a rare move, the China Food and Drug Administration has rejected 11 new drug applications (NDAs) from eight companies that were in its review queue, signaling more action to come as the agency increases punishments for clinical data forgery and prepares another intensive review campaign, its third in a decade.